RETEVMO vs SIROLIMUS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. RETEVMO and SIROLIMUS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	RETEVMO	SIROLIMUS
Rating	New	66/100
Pharmacy pays	—	~$48.61 /30
Type	RX	RX
Active ingredient	SELPERCATINIB	SIROLIMUS
Manufacturer	Eli Lilly and Co	Apotex
Dosage forms	Capsule, Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

retevmo sirolimus

Rating

New

66/100

Pharmacy pays

—

~$48.61 /30

Type

Active ingredient

SELPERCATINIB

SIROLIMUS

Manufacturer

Eli Lilly and Co

Apotex

Dosage forms

Capsule, Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Frequently asked questions

What is the difference between Retevmo and Sirolimus?

Retevmo contains Selpercatinib, while Sirolimus contains Sirolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.